Free To Choose Medicine

Free To Choose Medicine offers a compelling argument for the freedom of every patient, guided by the advice of his or her doctor, to make informed decisions about the use of not-yet-FDA-approved therapeutic drugs that are in late stages of clinical testing. After discussing the FDA’s current drug approval process, the author presents an easy-to-read, yet comprehensive case for the Free To Choose Medicine Act—a policy that would bring enormous benefits to patients in serious need of newly developed drugs, and that would reverse today’s trend toward increased governmental regulations. The book also deconstructs the false arguments of those who want to maintain the status quo of the FDA, or worse--those who demand ever-more-stringent FDA testing, which sometimes results in deadly over-caution. The passage of a Free To Choose Medicine Act would be a defining moment for Americans—a stake in the ground reminding us that control of medical decisions belongs, first and foremost, with individual patients and their doctors.

Free To Choose Medicine offers a compelling argument for the freedom of every patient, guided by the advice of his or her doctor, to make informed decisions about the use of not-yet-FDA-approved therapeutic drugs that are in late stages of clinical testing. After discussing the FDA’s current drug approval process, the author presents an easy-to-read, yet comprehensive case for the Free To Choose Medicine Act—a policy that would bring enormous benefits to patients in serious need of newly developed drugs, and that would reverse today’s trend toward increased governmental regulations. The book also deconstructs the false arguments of those who want to maintain the status quo of the FDA, or worse--those who demand ever-more-stringent FDA testing, which sometimes results in deadly over-caution. The passage of a Free To Choose Medicine Act would be a defining moment for Americans—a stake in the ground reminding us that control of medical decisions belongs, first and foremost, with individual patients and their doctors.

Bartley J. Madden retired as a Managing Director of Credit Suisse/Holt after a career in money management and investment research that included the founding of Callard Madden & Associates. During his career, he developed the CFROI valuation framework that is widely used today by money management firms worldwide. Madden is currently an independent researcher and a Senior Fellow at the National Center for Policy Analysis (NCPA). His research focuses on knowledge building and wealth creation as opposite sides of the same coin, and also on the application of systems thinking to public policy. His work on knowledge building is summarized in a YouTube video, “Management’s Worldview.” His work in finance and systems thinking is summarized in his book, Wealth Creation: A Systems Mindset for Building and Investing in Businesses for the Long Term. And his work in public policy has resulted in the Free To Choose Medicine plan, which was developed in journal articles published in Regulation, Cancer Biotherapy & Radiopharmaceuticals, and Medical Hypotheses.